CoChat

Actos Now for the prevention of diabetes (ACT NOW) study

Open access

The DOI matches its Crossref record; 54 of the 57 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

BACKGROUND: Impaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The purpose of the present study was to examine whether pioglitazone (ACTOS) can prevent progression of IGT to type 2 diabetes mellitus (T2DM) in a prospective randomized, double blind, placebo controlled trial. METHODS/DESIGN: 602 IGT subjects were identified with OGTT (2-hour plasma glucose = 140-199 mg/dl). In addition, IGT subjects were required to have FPG = 95-125 mg/dl and at least one other high risk characteristic. Prior to randomization all subjects had measurement of ankle-arm blood pressure, systolic/diastolic blood pressure, HbA1C, lipid profile and a subset had frequently sampled intravenous glucose tolerance test (FSIVGTT), DEXA, and ultrasound determination of carotid intima-media thickness (IMT). Following this, subjects were randomized to receive pioglitazone (45 mg/day) or placebo, and returned every 2-3 months for FPG determination and annually for OGTT. Repeat carotid IMT measurement was performed at 18 months and study end. Recruitment took place over 24 months, and subjects were followed for an additional 24 months. At study end (48 months) or at time of diagnosis of diabetes the OGTT, FSIVGTT, DEXA, carotid IMT, and all other measurements were repeated.Primary endpoint is conversion of IGT to T2DM based upon FPG >or= 126 or 2-hour PG >or= 200 mg/dl. Secondary endpoints include whether pioglitazone can: (i) improve glycemic control (ii) enhance insulin sensitivity, (iii) augment beta cell function, (iv) improve risk factors for cardiovascular disease, (v) cause regression/slow progression of carotid IMT, (vi) revert newly diagnosed diabetes to normal glucose tolerance. CONCLUSION: ACT NOW is designed to determine if pioglitazone can prevent/delay progression to diabetes in high risk IGT subjects, and to define the mechanisms (improved insulin sensitivity and/or enhanced beta cell function) via which pioglitazone exerts its beneficial effect on glucose metabolism to prevent/delay onset of T2DM. TRIAL REGISTRATION: clinical trials.gov identifier: NCT00220961.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1472-6823-9-17

Cites

54 of 57 references verified2 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 89

Metadata

Authors
DeFronzo, R. A., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R., Reaven, P. D., Schwenke, D., Stentz, F. B., & Tripathy, D.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • SUNY Downstate Health Sciences University (US)
  • Pennington Biomedical Research Center (US)
  • University of Southern California (US)
  • Georgetown University (US)
  • University of California San Diego (US)
  • University of Tennessee Health Science Center (US)
  • MedStar Health Research Institute (US)
  • Phoenix VA Health Care System (US)
Corresponding author
DeFronzo, Ralph A
Venue
BMC Endocrine Disorders
Published
2009-07-29
Volume
9
Issue
1
Pages
17-17
ISSN
1472-6823 (ISSN-L)
OpenAlex
W2015852718
Cited by
89
References
54
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 4 · 2013: 7 · 2012: 8
FWCI
11.90
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • BMC Endocrine Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
pioglitazone, impaired glucose tolerance, type 2 diabetes prevention, prediabetes, insulin sensitivity, beta-cell function, carotid intima-media thickness, cardiovascular risk factors, glycemic control, glucose metabolism, thiazolidinediones, glucose tolerance test, carotid ultrasound, body composition, HbA1c, lipid profile, blood pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Actos Now for the prevention of diabetes (ACT NOW) study. https://app.cochat.ai/papers/10.1186/1472-6823-9-17
The paper
DeFronzo, R. A., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R., Reaven, P. D., Schwenke, D., Stentz, F. B., & Tripathy, D. (2009). Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocrine Disorders. https://doi.org/10.1186/1472-6823-9-17

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.